BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29150335)

  • 1. Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
    Cincinelli R; Musso L; Artali R; Guglielmi M; Bianchino E; Cardile F; Colelli F; Pisano C; Dallavalle S
    Eur J Med Chem; 2018 Jan; 143():2005-2014. PubMed ID: 29150335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.
    Cincinelli R; Musso L; Artali R; Guglielmi MB; La Porta I; Melito C; Colelli F; Cardile F; Signorino G; Fucci A; Frusciante M; Pisano C; Dallavalle S
    PLoS One; 2018; 13(10):e0205018. PubMed ID: 30300374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A series of camptothecin prodrugs exhibit HDAC inhibition activity.
    Zhu Q; Yu X; Shen Q; Zhang Q; Su M; Zhou Y; Li J; Chen Y; Lu W
    Bioorg Med Chem; 2018 Sep; 26(16):4706-4715. PubMed ID: 30115492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents.
    Hong S; Shin Y; Jung M; Ha MW; Park Y; Lee YJ; Shin J; Oh KB; Lee SK; Park HG
    Eur J Med Chem; 2015; 96():218-30. PubMed ID: 25884112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
    Dallavalle S; Musso L; Cincinelli R; Darwiche N; Gervasoni S; Vistoli G; Guglielmi MB; La Porta I; Pizzulo M; Modica E; Prosperi F; Signorino G; Colelli F; Cardile F; Fucci A; D'Andrea EL; Riccio A; Pisano C
    Eur J Med Chem; 2022 Jan; 228():113971. PubMed ID: 34772529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and antitumor activity of non-camptothecin topoisomerase I inhibitors.
    Zhang C; Li S; Ji L; Liu S; Li Z; Li S; Meng X
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4693-6. PubMed ID: 26384290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-acting histone deacetylase-topoisomerase I inhibitors.
    Guerrant W; Patil V; Canzoneri JC; Yao LP; Hood R; Oyelere AK
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3283-7. PubMed ID: 23622981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of novel benzoxanthone analogues as non-Camptothecin topoisomerase I inhibitors.
    Cheng P; Zhu L; Guo W; Liu W; Yao J; Dong G; Zhang Y; Zhuang C; Sheng C; Miao Z; Zhang W
    J Enzyme Inhib Med Chem; 2012 Jun; 27(3):437-42. PubMed ID: 21770860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
    Liu W; Zhu L; Guo W; Zhuang C; Zhang Y; Sheng C; Cheng P; Yao J; Wang W; Dong G; Wang S; Miao Z; Zhang W
    Eur J Med Chem; 2011 Jun; 46(6):2408-14. PubMed ID: 21463912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
    Wang MJ; Liu YQ; Chang LC; Wang CY; Zhao YL; Zhao XB; Qian K; Nan X; Yang L; Yang XM; Hung HY; Yang JS; Kuo DH; Goto M; Morris-Natschke SL; Pan SL; Teng CM; Kuo SC; Wu TS; Wu YC; Lee KH
    J Med Chem; 2014 Jul; 57(14):6008-18. PubMed ID: 25003995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Biological Evaluation of 10-Substituted Camptothecin Derivatives with Improved Water Solubility and Activity.
    Yang XY; Zhao HY; Lei H; Yuan B; Mao S; Xin M; Zhang SQ
    ChemMedChem; 2021 Mar; 16(6):1000-1010. PubMed ID: 33241878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
    Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
    Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities.
    Guo W; Miao Z; Sheng C; Yao J; Liu W; Zhu L; Zhang Y; Cheng P; Dong G; Zhuang C; Zhang W
    Chem Biodivers; 2011 Jul; 8(7):1266-73. PubMed ID: 21766447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
    Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
    ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors.
    Miao Z; Zhu L; Dong G; Zhuang C; Wu Y; Wang S; Guo Z; Liu Y; Wu S; Zhu S; Fang K; Yao J; Li J; Sheng C; Zhang W
    J Med Chem; 2013 Oct; 56(20):7902-10. PubMed ID: 24069881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.